Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 15, 2022 | Post-IPO Equity | $74.75M | — | — | — | Detail |
Dec 14, 2022 | Post-IPO Debt | $175.25M | — | — | — | Detail |
Jul 7, 2020 | Grant | $1.60B | 1 | Government of United States of America | — | Detail |
Jun 15, 2020 | Post-IPO Equity | $200M | 1 | RA Capital Management | — | Detail |
May 11, 2020 | Grant | $384M | 1 | Coalition for Epidemic Preparedness Innovations | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Government of United States of America | Yes | Grant |
RA Capital Management | Yes | Post-IPO Equity |
Coalition for Epidemic Preparedness Innovations | Yes | Grant |
Bill & Melinda Gates Foundation | — | Grant |
Innovations Kapital | — | Post-IPO Equity |
Novavax has acquired 1 organizations. Their most recent acquisition was Isconova AB on Dec 2, 2013. They acquired Isconova AB for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Dec 2, 2013
Isconova AB
|
Biotechnology | acquisition | — | Detail |